Clinical evaluation of domperidone in the treatment of chronic postprandial idiopathic upper gastrointestinal distress.
Eleven patients with symptoms of chronic postprandial idiopathic upper gastrointestinal distress served as their own controls in a clinical trial of a new prokinetic agent, domperidone. After evaluations to eliminate the presence of anatomic lesions, each subject was given domperidone and placebo in random order for one month. Using a symptom-scoring questionnaire, no superiority of domperidone over placebo could be demonstrated in the group as a whole. Improvement in two out of three patients with diabetic gastroparesis, however, was noted. Side-effects possibly related to domperidone consisted of gas pains and skin rash in one patient each.